The causes of inflammatory pain and neuropathic pain are fundamentally different. There are, however, common mechanisms underlying the generation of each pain state. We will discuss some specific elements observed in both tissue and nerve injury pain states and consider the hypothesis that these two states actually demonstrate a convergence over time.
Introduction
Heuristically, the pain experience has been divided into three principal categories based on the initiating conditions and the anticipated underlying mechanisms: acute nociception, post-tissue injury/inflammation and postnerve injury.
Acute nociception
Acute (transient) high-intensity stimuli yield a somatotopically limited pain sensation that resolves upon the removal of the stimuli. The acute pain sensation is crucial to survival (witness the perilous existence of those who have no such acute sensation [1] ). The encoding of the stimulus involves specific activation of subpopulations of fast-conducting, lightly myelinated (A@) and slowconducting, unmyelinated (C) fibers which are endowed with their response property by virtue of specific channels expressed on their terminals. This acute afferent traffic leads to activation of supraspinally projecting dorsal horn neurons, the frequency of their activation being dependent upon the frequency of afferent input and accordingly stimulus intensity.
Tissue injury
Tissue injury arising from ongoing exposure to high-intensity stimuli leads to a pain sensation continuing beyond the removal of the originating stimulus. There is, in addition, an enhanced sensitivity to otherwise modestly aversive stimuli applied to the injured tissue (hyperalgesia). Typically such pain resolves in parallel with resolution of the injury state (e.g. healing). At the peripheral terminal, injury/inflammation leads to an innate immune cascade yielding release of active factors from blood, local and migrating inflammatory cells and injured cells. These products initiate activity in C fibers through eponymous receptors located on the afferent terminal and sensitize these terminals. At the level of the spinal dorsal horn, ongoing afferent traffic leads to initiation of a robust facilitation of dorsal horn output. The systems underlying this spinal facilitation include the following.
Enhanced postsynaptic transmission
(1) Enablement of the N-methyl-D-aspartate (NMDA) receptor by loss of the magnesium block [2]. (2) Increased trafficking of 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid (AMPA) receptor 
Spinobulbospinal pathway
Afferent input activates caudal midline raphe-spinal serotonergic neurons which terminate in dorsal horn neurons to facilitate the activity in deep dorsal horn projection systems [7, 8] .
Loss of local inhibition
Local dorsal horn neuronal excitability is under the tonic control of local inhibitory gamma-aminobutyric acid (GABA)ergic and glycinergic interneurons. Loss of this inhibitory control leads to potent allodynia [9] . Locally released prostaglandins have been shown to inhibit the function of glycine receptors, leading to a loss of local inhibition [10] .
Local non-neuronal cell systems
Peripheral inflammation leads to both acute and chronic indices of activation of spinal microglia and astrocytes. Activation of these cell systems has been shown to release a variety of proexcitatory neurohormones including cytokines, chemokines, ATP and protease-activated receptor (PAR) agonists [11] .
Migration of non-neuronal inflammatory cells into the dorsal root ganglion
Peripheral inflammation results in the appearance of macrophages in the dorsal root ganglion (DRG), but not the spinal cord [12] .
Peripheral nerve injury
Injury to the peripheral nerve leads to a pain state with persistency and components of hyperalgesia and allodynia (aversive sensation generated by an otherwise innocuous stimulus) referred to the distribution of the injured nerve. In these instances, evidence suggests that the ongoing sensations reflect the activation of small afferent traffic which arises from the distal spouting of the injured axons and from the DRG of the injured axon. The peripheral and spinal mechanisms underlying this increased spontaneous activity are broadly summarized in terms of the following.
Altered channel expression
Increased expression of a variety of sodium channels in the neuroma and in the DRG [13] , reduced expression of potassium channels [14, 15] and increased expression of a2d1, the auxiliary subunit of voltage-gated calcium channels [16, 17] has been noted.
Upregulation of markers for neuronal injury
Such markers include GAP43 [18] and activating transcription factor 3 (ATF3) [19] .
Increased expression of neuroma and dorsal root ganglion receptors
Receptors that are activated by products in the altered milieu have been shown including those for TNF-a, bradykinin, nerve growth factor and catecholamines [20] [21] [22] [23] .
Migration of non-neuronal inflammatory cells into the dorsal root ganglion
After nerve injury, increased macrophages and neutrophils have been shown in the DRG [24, 25] .
Activity-induced facilitation
The ongoing afferent traffic is believed to contribute importantly to the initiation of a central sensitization state with several components including activation of the NMDA receptors and increased AMPA subunit expression [26, 27] .
Loss of inhibition
Nerve injury leads to a change in the dorsal horn Cltransporters which in turn leads to a shift in the Clequilibrium potential such that increasing Clconductance will lead to a depolarization of the dorsal horn neurons rather than an inhibitory hyperpolarization [28] .
Spinobulbospinal facilitatory pathways
As noted above, spinobulbospinal pathways lead to the activation through the caudal midline raphe of serotonergic projections, which terminate in dorsal horn neurons to activate dorsal horn projection systems. Lesions of this system at the level of the ascending neurons [29] or at the descending link [30] [31] [32] abolish allodynia.
Pathophysiology of inflammatory and neuropathic pain Xu and Yaksh 401
Key points
Inflammatory pain and neuropathic pain can be distinguished from the following characteristics: resolution of pain, involvement of Ab afferent and pharmacology. Mechanisms common to both inflammatory and neuropathic pain include altered expression of cytokines, cytokine receptors and voltage-gated sodium channels in the DRG, enhanced glutamate release and receptor functions, disinhibition and glia activation and invasion in the spinal dorsal horn. Nerve injury marker ATF3 is observed in the DRG neurons following prolonged peripheral inflammation, suggesting the pain of inflammatory origin may evolve into a condition that resembles neuropathic pain.
Activation of non-neuronal cells
After nerve injury there are trophic changes in the appearance of microglia and astrocytes, suggesting increased activity of non-neuronal cells [11] .
Migration of non-neuronal inflammatory cells into dorsal horn
Peripheral nerve injury produces segmentally organized disruption of the blood-brain barrier [33 ] and the influx of T cells and macrophages [34] .
Separation of tissue versus neuropathic injury pain phenotypes
On the basis of the preceding overview, it can be seen that following peripheral tissue and nerve injury a variety of mechanisms are brought into play that alter nociceptive processing. Three characteristics would seem to firmly distinguish the two pain states.
Resolution of pain
Tissue injury-associated pain typically improves as a function of 'healing' and resolution of the inflammation.
In contrast neuropathic pain frequently does not show such reversal and persists despite an evident resolution of the injury with which the sensation is associated. We would note, however, that increasingly, there is an appreciation that in some instances the inflammatory/ injury state may resolve but a component of pain persists [35] . In humans a significant percentage of patients show this failure to resolve their pain after a variety of interventions including soft tissue resection [36] , herniorraphy [37] and joint repair [35] . In animals chronic inflammatory states may demonstrate a resolution of inflammation with a persistent allodynia [38 ] .
Role of low threshold afferent
The neuropathic allodynia almost certainly reflects the activation of Aß afferents in addition to an element of sensitized C fibers [39] . 
Pharmacology

As show in
Comparison of tissue versus neuropathic injury pain mechanisms
In the following sections we would like to discuss some specific elements observed in both tissue and nerve injury pain states and consider the hypothesis that these two states actually demonstrated a convergence over time ( Fig. 1 ).
TNF-alpha
TNF-a is a key regulator of the inflammatory response and is involved in increased production of proalgesic agents. Etanercept, a TNF-a inhibitor, has been effective for the treatment of rheumatoid arthritis and other inflammatory diseases [40] . Injection of TNF-a into sciatic nerve elicits hyperalgesia and allodynia that last for days, which is associated with nerve edema, Schwann cell injury and macrophage activation [41] .
It was later shown that topically applied TNF-a induced ectopic firing in C and A-delta fibers [42] .
Local TNF-a also lowered the mechanical threshold of C nociceptors and caused ongoing activity in some C nociceptors [43] . The level of TNF-a in DRG is increased after peripheral nerve injury [44] , as well as the two TNF-a receptors, TNFR1 and TNFR2 [22] . Normally expressed in mast cells, TNF-a following nerve injury is thought to be induced in infiltrating ED1 þ macrophages in a TLR2-dependent fashion [45 ] and Schwann cells [46] . In spinal nerve ligation rats, exogenously applied TNF-a is able to increase the sensitivity of both injured and adjacent uninjured DRG neurons. Injured DRG neurons not only respond to TNF-a at much lower concentrations but also exhibit enhanced discharges, a mechanism likely responsible for allodynia and spontaneous pain behavior [47] . TNF-a blockade prevented or reversed neuropathic pain in a number of animal models [48, 49] . Recent work has shown that epidural TNF-a block relieves sciatica pain in humans [50] . 
Voltage-gated sodium channels
Voltage-gated sodium channels (VGSCs) control the propagation of nerve impulses and are therefore essential for the excitability of neurons. Sodium channel blockers, such as local anaesthetics, are a mainstay of pain medicine. Several VGSC members are implicated in persistent pain, including Nav1.3, Nav1.7 and Nav1.8 [13, 51] . Mutations of Nav1.7 are linked to several rare human pain disorders including erythromelalgia (gain of function) [52] and congenital insensitivity to pain (nonsense mutation, loss of function) [1]. Nav1.7 is highly expressed in nociceptors. An increased level of Nav1.7 was seen following peripheral inflammation, mediated by cyclooxygenase (COX)dependent mechanisms [53] . Disrupting Nav1.7 in nociceptors attenuated pain hypersensitivity in several inflammatory pain models [54] . Interestingly, neuropathic pain developed normally in those Nav1.7 knockout mice [55] . It should be noted the knockout of Nav1.7 was limited to nociceptors that co-express Nav1.8. It is therefore possible that other groups of Nav1.7 primary afferents or other sodium channels contribute to neuropathic pain.
Nav1.8 is selectively expressed in nociceptors. Rapid increase in Nav1.8 level is induced by a number of inflammatory mediators [51] and disrupting Nav1.8 abolished inflammatory pain [55] . Certain types of neuropathic pain, however, are preserved not only in animals with Nav1.8 knockout but also in animals with the Nav1.8-expressing nociceptors ablated [56] , suggesting there are distinct pathways governing inflammatory versus neuropathic pain at the primary afferent level.
Transection of the L5 ventral root produces prolonged allodynia [57] . Recent studies demonstrated that Nav1.8 is upregulated in the uninjured L4 and L5 DRG after L5 ventral root transection [58 ,59 ] . The increased membrane expression of Nav1.8 leads to spontaneous repetitive discharge, a mechanism for spontaneous pain. Small molecules that selectively inhibit Nav1.7 and/or Nav1.8 for the treatment of neuropathic pain are under active investigation.
Voltage-gated calcium channels
Voltage-gated calcium channels (VGCCs) are critical in controlling neurotransmitter release. Several VGCCs are detected in DRG neurons and implicated in pain. Inhibitors for N, T and L-type VGCCs are used clinically to alleviate neuropathic pain [60] . The VGCC accessory subunit a2d1, the main target for gabapentin and pregabalin, is upregulated in injured DRG neurons [16, 17] . a2d1 facilitates trafficking of Cav2.1 into the cell membrane [61] , thereby modulating excitability of DRG neurons. The role of a2d1 in neuropathic pain is supported by the efficacy of gabapentin and pregabalin in the treatment of neuropathic pain patients, as well as preclinical findings that intrathecal antisense oligonucleotides against the a2d1 subunit block neuropathic pain [62] [63] [64] . Changes in a2d1 expression are not reported in inflammatory pain. Gabapentin, however, does inhibit inflammatory pain in preclinical models, suggesting a mechanism independent of one requiring increased a2d1 subunit expression [38 ,65] .
Altered gene expression in dorsal root ganglion neurons
Nerve lesion induces expression of genes that are related to regeneration, such as ATF3 [19] . Overexpression of ATF3 promotes neurite outgrowth in culture DRG neurons [66] . In transgenic mice that constitutively express ATF3 in the DRG neurons, the rate of nerve regeneration following injury is significantly increased [67] . There is a certain degree of correlation between the type of stimuli and the subpopulation of sensory neurons that show ATF3 expression. Thus hindpaw injections of capsaicin, mustard oil or menthol induced expression of ATF3 in DRG neurons that express the expected TRP channel subtypes [68 ] . The induction of ATF3 seems rather selective for compounds or insults that may lead to nerve injury. Agents that cause inflammation, such as carrageenan or complete Freund's adjuvant (CFA), do not induce ATF3 expression [68 ] , suggesting nerve injury, rather than the mere increased activity is required. Using DRG ATF3 as a marker, a role of nerve injury has been revealed in persistent pain following back skin incision [69 ] . DRG ATF3 expression was also noticed in the K/BxN mouse arthritis model, but only in the late phase when the peripheral inflammation was fully resolved [38 ] . This 'late' pain is associated with a loss of response to NSAIDs, suggesting the pain of inflammatory origin evolved into a condition that is similar to neuropathic pain. Revealing the signaling events surrounding ATF3 activation might hold the key to the understanding of the transition from acute to chronic pain.
VGLUT and central terminal glutamate release
Glutamate is the major excitatory neurotransmitter in the CNS. Glutamatergic activity is regulated by removal of glutamate from the synaptic cleft by both neurons and astrocytes [70] . Once in the cell, vesicular glutamate transporters (VGLUT1-VGLUT3) mediate glutamate uptake into vesicles from which glutamate can be released in a calcium-dependent fashion [71] . Null mutation of VGLUT1 and VGLUT2 are lethal [72] [73] [74] . Heterozygote mice are viable and relatively normal. Whereas heterozygous VGLUT1 mice did not show significant changes in their pain behaviors, global reduction of VGLUT2 attenuated some aspects of neuropathic pain [75] . Further studies were carried out in mice with conditional knockout of VGLUT2 in DRG neuron subpopulations defined by the expression of peripherin, Nav1.8 and tyrosine hydroxylase. All of these conditional knockout animals showed deficits to some degree in acute and chronic pain, although the phenotypes do not completely overlap [76 -78 ] . In all cases, attenuated nociception is associated with reduced firing of superficial dorsal horn neurons or c-fos expression, confirming a key role for glutamate release from the central terminals.
The role of VGLUT3 is less understood. VGLUT3 is expressed in a small group of DRG neurons, with their central afferents terminating in the superficial layer of spinal dorsal horn. VGLUT3 knockout animals do not develop mechanical hypersensitivity in models of inflammatory pain and neuropathic pain, whereas noxious heat sensation is largely intact. In addition, VGLUT3 appears to be primarily responsible for transport of glutamate into astrocyte vesicles [79] , which can subsequently be released by astrocyte activation.
Postsynaptic activation
Release of glutamate in the spinal dorsal horn leads to activation of a variety of ionotrophic receptors. The importance of this release is indicated by the fact that AMPA receptor blockade results in a virtual complete block of acute postsynaptic excitation, whereas blockade of the NMDA receptor has little effect upon acute excitation, but can markedly diminish the initiation of the enhanced response of spinal neurons to repetitive small afferent input (e.g. wind up) [27] .
In response to peripheral inflammation and increased primary afferent traffic, synaptic efficacy in the spinal cord dorsal horn is strengthened, which in part results from the enhanced function of postsynaptic glutamate receptors [27] . For example, intraplantar CFA promotes trafficking of NR2B to synapses in the spinal cord dorsal horn [80] . NMDA receptors containing NR2B have slower decay kinetics therefore allow more Ca 2þ influx, leading to hyperactivity of second-order neurons. Changes in channel properties are extensively studied for AMPA receptors. Kopach et al. [81] showed that extrasynaptic GluR1 containing AMPARs is significantly increased in the tonically firing substantia geletinosa neurons. Choi et al. [82 ] showed that the trafficking of GluR1 to neuron membrane is TNF-adependent. GluR1 containing AMPARs are permeable to Ca 2þ . Thus, the increase of GluR1 at synaptic sites enhances Ca 2þ influx and the excitability of dorsal horn neurons.
Disinhibition
Dorsal horn nociceptive neurons are under powerful inhibitory control. Intrathecal strychnine (glycine receptor antagonist) or bicuculline (GABA A receptor antagonist) evokes immediate tactile allodynia, but had no effect upon thermal escape thresholds [9] , suggesting that tonic or evoked glycinergic or GABAergic inhibition in the spinal cord is crucial to the encoding of low threshold mechanical (tactile) stimuli as a nonaversive stimulus. GABA and glycinergic interneurons have indeed been shown to exert a potent regulation of large primary afferent terminal and postsynaptic excitability through their respective receptors, which are Clionophores. Loss of this GABAergic/glycinergic inhibition would thus permit an enhanced activation, resulting from decreased numbers or content of glycine and/or GABA [83, 84] , attenuated function or lowered expression of glycine and/or GABA receptors, and/or GABAergic excitation. For dorsal horn neurons, the equilibrium potential of Cl À is such that the opening of GABA A receptors or glycine channels causes an influx of Cl À and hyperpolarization. Reduced activity of K þ -Cl À co-transporter (KCC) and/or enhanced activity of Na þ -K À -Cl À co-transporter (NKCC) could lead to increased intracellular Cl À ; therefore the opening of GABA A channel induces depolarization and excitation of dorsal horn nociceptive neurons. This mechanism is implicated in both inflammatory pain and neuropathic pain [85] . Reduced spinal expression of KCC2 is noticed following intraplantar formalin [86] or CFA [87] , as well as nerve injury [28] . Fast phosphorylation of dorsal horn NKCC1 is seen within 10 min after intracolonic capsaicin injection [88] . The phosphorylation likely promotes membrane trafficking of NKCC1 and might play a role in referred mechanical hyperalgesia. Intraplantar capsaicin produced a significant enhancement in spike frequency in both wide dynamic range (WDR) and nociceptive-specific neurons in dorsal horn. Spinal blockade of NKCC1 normalized the spike frequency to baseline levels, suggesting that NKCC1 plays a key role in the sensitization of dorsal horn neurons [89 ] .
Involvement of spinal glia
It is increasingly recognized that glias, especially microglias, play important roles in the generation of chronic pain [90] [91] [92] . A number of factors contribute to dorsal horn microglia activation following tissue/nerve injury, including TNF-a, PGE2, ATP and IL-6. Mice deficient in PGE 2 production have impaired dorsal horn activation of microglia and do not exhibit mechanical allodynia after peripheral nerve injury [93 ] . This study revealed that PGE2 acts through both EP1 and EP2 to retain microglia in the central terminal of primary afferents. IL-6, a proinflammatory cytokine, is induced in the dorsal horn following nerve injury and is involved in the early activation of the JAK/STAT3 pathway [94] . JAK/STAT3 in turn stimulates the production of more IL-6 and CC chemokine ligand CCL2. In addition, IL-6 activates microglial p38 MAPK pathway-mediated expression of fractalkine receptor CX3CR1 [95] , thereby promoting the interaction between dorsal horn neurons and microglia. Proinflammatory cytokines release from activated microglia modulates neuronal synaptic transmission. TNF-a, for example, rapidly inhibited spontaneous action potentials in GABAergic neurons in a p38-dependent fashion, leading to disinhibition [96 ] .
In addition to its role in cytokine production, activated microglia could assume an amoeboid shape and act similar to a macrophage. Following peripheral nerve injury, microglia in lamina II-III were shown to engulf both injured and uninjured myelinated axons, a phenomenon not observed in the normal dorsal horn [97 ] . The engulfment of axons likely induces injuries to spinal cord neurons, as indicated by the dorsal horn expression of ATF3. Thus microglia activation may introduce central pain components to an existing peripheral neuropathic pain.
Conclusion
There is no doubt that inflammatory pain and neuropathic pain share common mechanisms, although the time course and relative contribution of each of these mechanisms might be different. A more precise depiction of these differences is critical in providing the rationale for a timely intervention, which might prevent the transition from acute pain to a persistent, chronic state. It becomes clear that a successful approach is likely to involve not only analgesics, but also means that may modify the progression of pain as a disease.
